{"filing": {"accession": "0001601830-26-000128", "cik": "0001601830", "ticker": "RXRX", "company_name": "RECURSION PHARMACEUTICALS, INC.", "form_type": "8-K", "filing_type": "8-K", "filing_date": "2026-10-15", "accepted_datetime": null, "acceptance_datetime": null, "accepted_at": null, "primary_doc_url": "https://www.sec.gov/Archives/edgar/data/1601830/000160183026000128/0001601830-26-000128-index.htm", "filing_url": "https://www.sec.gov/Archives/edgar/data/1601830/000160183026000128/0001601830-26-000128-index.htm", "period_of_report": "2026-10-15"}, "html_url": "/api/filings/000160183026000128/stream", "exhibits": [{"exhibit_number": "1.1", "exhibit_type": "1", "description": "Underwriting Agreement, dated as of October 15, 2026 by and between Recursion Pharmaceuticals, Inc., and Leerink Partners LLC, Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC,, and Evercore Group L.L.C. as representatives of the several underwriters named therein.", "filename": "exhibit11-2026underwriting.htm", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1601830/000160183026000128/exhibit11-2026underwriting.htm", "category": "debt", "incorporated_by_reference": false}, {"exhibit_number": "5.1", "exhibit_type": "5", "description": "Opinion of Wilson Sonsini Goodrich & Rosati.", "filename": "exhibit51opinionofcounsel.htm", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1601830/000160183026000128/exhibit51opinionofcounsel.htm", "category": "other", "incorporated_by_reference": false}, {"exhibit_number": "23.1", "exhibit_type": "23", "description": "Consent of Wilson Sonsini Goodrich & Rosati (included in Exhibit 5.1).", "filename": "exhibit51opinionofcounsel.htm", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1601830/000160183026000128/exhibit51opinionofcounsel.htm", "category": "other", "incorporated_by_reference": false}, {"exhibit_number": "99.1", "exhibit_type": "99", "description": "Press Release of Recursion Pharmaceuticals, Inc. dated October 15, 2026.", "filename": "exhibit991-sanofipr.htm", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1601830/000160183026000128/exhibit991-sanofipr.htm", "category": "other", "incorporated_by_reference": false}, {"exhibit_number": "99.2", "exhibit_type": "99", "description": "Press Release of Recursion Pharmaceuticals, Inc. dated October 15, 2026.", "filename": "exhibit992-businessupdate.htm", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1601830/000160183026000128/exhibit992-businessupdate.htm", "category": "other", "incorporated_by_reference": false}, {"exhibit_number": "99.3", "exhibit_type": "99", "description": "Corporate Presentation of Recursion Pharmaceuticals, Inc. dated October 15, 2026.", "filename": "rxrx_octoberx2026xfinal.htm", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1601830/000160183026000128/rxrx_octoberx2026xfinal.htm", "category": "other", "incorporated_by_reference": false}, {"exhibit_number": "99.4", "exhibit_type": "99", "description": "Press Release of Recursion Pharmaceuticals, Inc. dated October 15, 2026.", "filename": "exhibit994-pricingpr.htm", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1601830/000160183026000128/exhibit994-pricingpr.htm", "category": "other", "incorporated_by_reference": false}], "sections": [], "tables": [{"table_index": 0, "table_type": "text", "caption": null, "header_text": ""}, {"table_index": 1, "table_type": "text", "caption": null, "header_text": ""}, {"table_index": 2, "table_type": "exhibit_index", "caption": null, "header_text": ""}, {"table_index": 3, "table_type": "text", "caption": null, "header_text": ""}], "exhibits_pending": false, "cdn_html": true, "response_time_ms": 30}